

# Trends in Pharmacological Sciences

March 2023, Volume 44, Number 3, pp. 131–192

## Spotlights

- 131 **Giving ERK a jERK from the endosome** *Evi Kostenis, Sergi Bravo, and Jesus Gomeza*
- 134 **Taming PRMT5–adaptor protein interactions** *Hunter S. Sims and Mingji Dai*

## Opinions

- 137 **Advances and challenges in therapeutic targeting of NRF2** *Albena T. Dinkova-Kostova and Ian M. Copple*
- 150 **Targeting *in silico* GPCR conformations with ultra-large library screening for hit discovery** *D. Sala, H. Batebi, K. Ledwitch, P.W. Hildebrand, and J. Meiler*
- 162 **Developing novel antifungals: lessons from G protein-coupled receptors** *Vaithish Velazhahan, Bethany L. McCann, Elaine Bignell, and Christopher G. Tate*

## Review

- 175 **Computational and artificial intelligence-based methods for antibody development** *Jisun Kim, Matthew McFee, Qiao Fang, Osama Abidin, and Philip M. Kim*

## Drug of the Month

- 190 **Futibatinib (Lytgobi) for cholangiocarcinoma** *Robert Roskoski Jr*

## Editor

Jerry Madukwe

## Trends Publisher

Danielle Loughlin

## Journal Manager

Fred Kop

## Journal Administrator

Patrick Scheffmann

## Advisory Board

Michelle Arkin  
Matthew Banks  
Andrew Bate  
Mary Bebawy  
Jeffrey Benovic  
Jacqueline N. Crawley  
Debbie L. Hay  
Stephanie Harlfinger  
Laszlo Hunyady  
Magnus Ingelman-Sundberg  
Michael Kassiou  
Kum Kum Khanna  
Brian K. Kobilka  
Jenny K.W. Lam  
Michel Lazdunski  
Fiona H. Marshall  
Ruth Nussinov  
Avner Schlessinger  
Martina Schmidt  
Harald Sitte  
Rachel F. Tyndale  
Ming-Wei Wang  
Stephen P. Watson  
Stephen G. Waxman  
Matthew Webber



**On the cover:** Recent progress has been made in fungal G protein-coupled receptor (GPCR) structure characterization that presents novel opportunities for drug design targeting fungal membrane proteins (GPCRs and ion channels). In an article of this issue, Velazhahan, Tate, and colleagues discuss these opportunities leveraging GPCR structure-based drug design and development paradigms. The cover image depicts a structural homodimer model (view parallel to the membrane plane) of yeast GPCR (Ste2) in the antagonist-bound state. Ste2A (gray ribbon), Ste2B (blue ribbon), cholesterol hemisuccinate (orange), N-acetylglucosamine molecules (black), antagonist (yellow or green). Heteroatom representation: oxygen, red; nitrogen, blue. Image credit: adapted from Figure 3 of Velazhahan *et al.*

## Editorial Inquiries

*Trends in Pharmacological Sciences*  
Cell Press  
50 Hampshire St. 5th Floor  
Cambridge, MA 02139, USA  
Tel: 617 397 2800  
E-mail: [tips@cell.com](mailto:tips@cell.com)

